Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6
clinical trial
Press Enter · cited answer in seconds
0 sources
Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6
Summary
Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6 is a clinical trial[1].
Key Facts
- Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6's instance of is recorded as clinical trial[2].
- Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6's start time is recorded as +2018-07-30T00:00:00Z[3].
- Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6's end time is recorded as +2020-07-29T00:00:00Z[4].
- Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6's main subject is recorded as carcinoma[5].
- Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6's number of participants is recorded as {'unit': '1', 'amount': '+43'}[6].
- Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6's title is recorded as Safety and Efficacy of Intraperitoneal Paclitaxel in Gastric Cancer Patients With Peritoneal Metastasis Receiving Systemic Chemotherapy[7].
- Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6's short name is recorded as IPLUS[8].
- Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+20'}[9].
- Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6's ClinicalTrials.gov ID is recorded as NCT03618758[10].
- Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+79'}[11].
- Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6's research intervention is recorded as paclitaxel[12].
- Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6's clinical trial phase is recorded as phase I clinical trial[13].
- Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6's clinical trial phase is recorded as phase II clinical trial[14].
- Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6's research site is recorded as Seoul National University Bundang Hospital[15].
- Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6's research subject recruitment status is recorded as recruiting[16].
- Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6's study type is recorded as interventional study[17].